导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.61% | 2365/4773 |
| 近一周 | -2.41% | 2096/5462 |
| 近一月 | -4.57% | 2569/5421 |
| 近一季 | -8.08% | 2673/5209 |
| 近半年 | -3.98% | 2384/4920 |
| 近一年 | 2.59% | 2087/4366 |
| 近两年 | 54.46% | 1357/2954 |
| 近三年 | 31.94% | 969/2253 |
| 成立以来 | 44.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.21% 2716/4961 |
14.56% 1795/5312 |
- - |
- - |
| 2025 | 23.49% 1868/4813 |
-0.23% 2120/3635 |
2.22% 1750/4076 |
20.62% 1948/4524 |
0.39% 2022/4813 |
| 2024 | 15.11% 966/3463 |
1.59% 874/2808 |
-2.21% 1153/3014 |
17.54% 1168/3129 |
-1.42% 1696/3463 |
| 2023 | -8.17% 984/2656 |
5.62% 765/2280 |
-4.00% 1006/2385 |
-3.36% 907/2515 |
-6.28% 1701/2655 |
| 2022 | -19.33% 834/2207 |
-14.21% 919/1919 |
6.23% 746/2016 |
-13.36% 891/2113 |
2.18% 1016/2208 |
| 2021 | 2.04% 640/1822 |
-2.68% 691/1255 |
5.95% 779/1330 |
-3.07% 610/1466 |
2.09% 702/1822 |
| 2020 | 29.94% 527/1250 |
-9.54% 686/1028 |
14.75% 536/1067 |
12.45% 384/1164 |
11.31% 551/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 添富中证800ETF VS. 长安沪深300非周期A(740101) |